JP2021507698A5 - - Google Patents

Info

Publication number

JP2021507698A5

JP2021507698A5 JP2020533185A JP2020533185A JP2021507698A5 JP 2021507698 A5 JP2021507698 A5 JP 2021507698A5 JP 2020533185 A JP2020533185 A JP 2020533185A JP 2020533185 A JP2020533185 A JP 2020533185A JP 2021507698 A5 JP2021507698 A5 JP 2021507698A5

Authority

JP

Japan

Prior art keywords

antigen

amino acid

seq

binding

domain

Prior art date

2018-12-20

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000427 antigen Substances 0.000 claims 81
• 102000036639 antigens Human genes 0.000 claims 81
• 108091007433 antigens Proteins 0.000 claims 81
• 125000003275 alpha amino acid group Chemical group 0.000 claims 38
• 235000001014 amino acid Nutrition 0.000 claims 13
• 206010028980 Neoplasm Diseases 0.000 claims 8
• 201000011510 cancer Diseases 0.000 claims 8
• 239000003814 drug Substances 0.000 claims 6
• 238000006467 substitution reaction Methods 0.000 claims 6
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 4
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 4
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 4
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 4
• 102000025850 HLA-A2 Antigen Human genes 0.000 claims 4
• 108010074032 HLA-A2 Antigen Proteins 0.000 claims 4
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
• 125000000539 amino acid group Chemical group 0.000 claims 4
• 210000004899 c-terminal region Anatomy 0.000 claims 4
• 201000010099 disease Diseases 0.000 claims 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
• 235000013922 glutamic acid Nutrition 0.000 claims 4
• 239000004220 glutamic acid Substances 0.000 claims 4
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims 4
• 239000004475 Arginine Substances 0.000 claims 3
• 239000004472 Lysine Substances 0.000 claims 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 3
• 102000040430 polynucleotide Human genes 0.000 claims 3
• 108091033319 polynucleotide Proteins 0.000 claims 3
• 239000002157 polynucleotide Substances 0.000 claims 3
• 229920001184 polypeptide Polymers 0.000 claims 3
• 102000004196 processed proteins & peptides Human genes 0.000 claims 3
• 239000013598 vector Substances 0.000 claims 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 2
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
• 235000003704 aspartic acid Nutrition 0.000 claims 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
• 210000004027 cell Anatomy 0.000 claims 2
• 201000005787 hematologic cancer Diseases 0.000 claims 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
• 208000032839 leukemia Diseases 0.000 claims 2
• 238000004519 manufacturing process Methods 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
• 102000009109 Fc receptors Human genes 0.000 claims 1
• 108010087819 Fc receptors Proteins 0.000 claims 1
• 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
• 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 239000012636 effector Substances 0.000 claims 1
• 239000013604 expression vector Substances 0.000 claims 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 239000000126 substance Substances 0.000 claims 1
• 239000004308 thiabendazole Substances 0.000 claims 1
• 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1